Grants Search Results

Osteosarcoma is a cancer of bone that typically affects teenagers and young adults. Tumor spread (or metastasis) to the lungs is common, and up to 40% of patients with osteosarcoma will eventually experience a cancer recurrence (or relapse). Unfortunately, no therapies have shown benefit following relapse and these patients have a very poor prognosis. The ability of cancer to control and hide from the body’s immune system is important for tumor growth and metastasis, so preventing these functions is an important treatment strategy. Recent work, including a canine osteosarcoma trial, has shown that currently available medications may work together to block some of the effects that cancer has on the immune system, reducing tumor growth and the ability to spread. Dr. Faulk will conduct a clinical trial which will combine these drugs (losartan and sunitinib) in children and young adults with relapsed osteosarcoma to test the safety of the new combination, see how the drugs are broken down by the body, and determine how the drugs affect the immune system and the growth of the tumor.

In the U.S., children with a blood cancer called Hodgkin lymphoma (HL) are usually treated successfully. Some of these children will suffer health problems several years later because of the treatment they received. Because of this, doctors use powerful imaging tools to identify patients who are likely to do well or not. Those who are likely to do well require less treatment and those who are less likely to do well can receive more treatment. But in low-income countries like Malawi, these tools are unavailable, and the children there often receive treatment that may be unnecessary. Scientists have found unique abnormalities in adults with HL that can tell us who is less likely to do well. Here, Dr. Ozuah is testing whether these abnormalities are present in children and could be used to decide how best to treat children with HL in low-middle income countries

With increased survival for children with cancer, efforts that prevent long-term health problems are important for improving the quality of life and life expectancy of these children. Diet and fitness are two critical factors for healthy survivorship, but interventions for survivors of childhood cancer have had limited impact, focus almost exclusively on physical activity, and often exclude caregivers, the primary nutrition gatekeepers in the home. Although research supports a key role for the gastrointestinal (GI) microbiome in regulating weight and health outcomes, no studies have examined the “obesogenic” microbiome in the context of interventions for these survivors. Harvesting Hope for Kids (HH4K) is a unique, biobehavioral lifestyle intervention delivered over 8 weeks during the summer in a university-based, cancer survivor garden. It was adapted from a successful intervention for survivors of adult-onset cancer, with pilot data supporting its feasibility in children. In line with St. Baldrick’s mission to improve outcomes for children with cancer, this randomized controlled trial is evaluating the efficacy of HH4K to improve dietary and physical activity patterns in 40 survivors of pediatric cancer (i.e., ages 8-12; < 2 years off treatment). Results will support a larger, multi-institutional trial and improve survivorship care to prevent costly, long-term morbidity.

In the U.S., children with a blood cancer called Hodgkin lymphoma (HL) are usually treated successfully. Some of these children will suffer health problems several years later because of the treatment they received. Because of this, doctors use powerful imaging tools to identify patients who are likely to do well or not. Those who are likely to do well require less treatment and those who are less likely to do well can receive more treatment. But in low-income countries like Malawi, these tools are unavailable, and the children there often receive treatment that may be unnecessary. Scientists have found unique abnormalities in adults with HL that can tell us who is less likely to do well. Here, Dr. Ozuah is testing whether these abnormalities are present in children and could be used to decide how best to treat children with HL in low-middle income countries

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Langerhans Cell Histiocytosis (LCH) is a potentially fatal disease characterized by inflammatory tumors. Recently, researchers discovered that LCH arises from immature immune cells in the blood and is in fact a form of cancer. It is not known why some children develop extensive life-threatening disease, others may have limited tumors, and some develop progressive brain deterioration. In this study, Dr. Allen is investigating the role of inherited genes, acquired gene mutations, and the origin of tumor cells to define the causes of LCH. The ultimate goal is to develop personalized approach to determine the safest, most effective therapy for each child.

This grant is generously supported by the Move For Miles Childhood Cancer Foundation, a St. Baldrick's partner. Inspired by Miles Dagelewicz who was diagnosed with Langerhans Cell Histiocystosis, a rare cancer at one year old, the Foundation was created to support childhood cancer research through Powerful Play and to create “sMiles” for families in treatment.  Rooted in the belief that they must always be moving forward for better treatments, cures, and long-term quality of life for survivors, the organization strives to achieve their goals by harnessing the most natural childhood pastime ... what they call Powerful Play.

Dr. Kentsis is working to advance both our basic scientific knowledge about how young people develop cancer, and to use that knowledge to discover and develop new treatments for children that are precise, curative and safe. The St. Baldrick’s Robert J. Arceci Innovation Award is given in honor of the late Dr. Robert Arceci. A pioneer in the field, this award reflects Dr. Arceci’s values including creativity, collaboration, and commitment to early- to mid-career scientists.

This grant supports clinical research staff to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports the efforts to translate clinical trial materials to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure. Maimonides Medical Center is the only designated cancer center in Brooklyn, NY, home to over 600,000 children, two-thirds of whom are minorities.

This grant supports a Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Coordinator for the bone marrow tranplantation program, to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Nurse Navigator for adolescents and young adults at Stony Brook Cancer Center, with a particular focus on increased clinical trial enrollment.

This grant supports a Clinical Research Coordinator to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports clinical research staff to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a clinical research protocol writer to ensure that more kids can be treated on clinical trials, often their best hope for a cure.